2024 is expected to be the year when a majority of clinical trials will be decentralized – and biopharma companies that prepare for this change slowly can expect to lose market share quickly. Decentralized and hybrid clinical trials eliminate geographic barriers and improve patient participation rates and diversity – as long as your teams are properly trained and have the right partners and technology.

DGE invites you to return to the industry’s first, most detailed, and most trusted conference on this topic – the 8th Decentralized & Hybrid Clinical Trials conference! Join us in May in Philadelphia for all-new analyses of upscaling digital technologies, refining recruitment strategy, benefiting from retail pharmacy partners – and much more!